Cargando…

Investigating the Implications of CFTR Exon Skipping Using a Cftr Exon 9 Deleted Mouse Model

Introduction: Severity and disease progression in people with Cystic Fibrosis (CF) is typically dependent on their genotype. One potential therapeutic strategy for people with specific mutations is exon skipping with antisense oligonucleotides (AO). CFTR exon 9 is an in-frame exon and hence the excl...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinovich, Kelly M., Kicic, Anthony, Stick, Stephen M., Johnsen, Russell D., Fletcher, Sue, Wilton, Steve D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981082/
https://www.ncbi.nlm.nih.gov/pubmed/35392567
http://dx.doi.org/10.3389/fphar.2022.868863
_version_ 1784681527696687104
author Martinovich, Kelly M.
Kicic, Anthony
Stick, Stephen M.
Johnsen, Russell D.
Fletcher, Sue
Wilton, Steve D.
author_facet Martinovich, Kelly M.
Kicic, Anthony
Stick, Stephen M.
Johnsen, Russell D.
Fletcher, Sue
Wilton, Steve D.
author_sort Martinovich, Kelly M.
collection PubMed
description Introduction: Severity and disease progression in people with Cystic Fibrosis (CF) is typically dependent on their genotype. One potential therapeutic strategy for people with specific mutations is exon skipping with antisense oligonucleotides (AO). CFTR exon 9 is an in-frame exon and hence the exclusion of this exon would excise only 31 amino acids but not alter the reading frame of the remaining mRNA. Splice mutations 1209 + 1 G > C and 1209 + 2 T > G were documented to cause CFTR exon 9 skipping and these variants were reported to manifest as a milder CF disease, therefore exon 9 skipping could be beneficial for people with class I mutations that affect exon 9 such as p.Trp401X. While the impact of exon 9 skipping on gene expression and cellular pathways can be studied in cells in vitro, trace amount of full-length normal or mutated material could confound the evaluation. To overcome this limitation, the impact of CFTR exon 9 skipping on disease phenotype and severity is more effectively evaluated in a small animal model. It was hypothesised that antisense oligonucleotide-mediated skipping this particular exon could result in a “mild mouse CF phenotype”. Methods: Cftr exon 9 deleted mice were generated using homologous recombination. Survival of homozygous (Cftr ( Δ9/Δ9 )) and heterozygous (Cftr ( Δ9/+ )) mice was compared to that of other CF mouse models, and lung and intestinal organ histology examined for any pathologies. Primary airway epithelial cells (pAECs) were harvested from Cftr ( Δ9/Δ9 ) mice and cultured at the Air Liquid Interface for CFTR functional assessment using Ussing Chamber analysis. Results: A Cftr ( Δ9/Δ9 ) mouse model presented with intestinal obstructions, and at time of weaning (21 days). Cftr ( Δ9/Δ9 ) mice had a survival rate of 83% that dropped to 38% by day 50. Histological sections of the small intestine from Cftr ( Δ9/Δ9 ) mice showed more goblet cells and mucus accumulation than samples from the Cftr ( Δ9/+ ) littermates. Airway epithelial cell cultures established from Cftr ( Δ9/Δ9 ) mice were not responsive to forskolin stimulation. Summary: The effect of Cftr exon 9 deletion on Cftr function was assessed and it was determined that the encoded Cftr isoform did not result in a milder “mouse CF disease phenotype,” suggesting that Cftr exon 9 is not dispensable, although further investigation in human CF pAECs would be required to confirm this observation.
format Online
Article
Text
id pubmed-8981082
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89810822022-04-06 Investigating the Implications of CFTR Exon Skipping Using a Cftr Exon 9 Deleted Mouse Model Martinovich, Kelly M. Kicic, Anthony Stick, Stephen M. Johnsen, Russell D. Fletcher, Sue Wilton, Steve D. Front Pharmacol Pharmacology Introduction: Severity and disease progression in people with Cystic Fibrosis (CF) is typically dependent on their genotype. One potential therapeutic strategy for people with specific mutations is exon skipping with antisense oligonucleotides (AO). CFTR exon 9 is an in-frame exon and hence the exclusion of this exon would excise only 31 amino acids but not alter the reading frame of the remaining mRNA. Splice mutations 1209 + 1 G > C and 1209 + 2 T > G were documented to cause CFTR exon 9 skipping and these variants were reported to manifest as a milder CF disease, therefore exon 9 skipping could be beneficial for people with class I mutations that affect exon 9 such as p.Trp401X. While the impact of exon 9 skipping on gene expression and cellular pathways can be studied in cells in vitro, trace amount of full-length normal or mutated material could confound the evaluation. To overcome this limitation, the impact of CFTR exon 9 skipping on disease phenotype and severity is more effectively evaluated in a small animal model. It was hypothesised that antisense oligonucleotide-mediated skipping this particular exon could result in a “mild mouse CF phenotype”. Methods: Cftr exon 9 deleted mice were generated using homologous recombination. Survival of homozygous (Cftr ( Δ9/Δ9 )) and heterozygous (Cftr ( Δ9/+ )) mice was compared to that of other CF mouse models, and lung and intestinal organ histology examined for any pathologies. Primary airway epithelial cells (pAECs) were harvested from Cftr ( Δ9/Δ9 ) mice and cultured at the Air Liquid Interface for CFTR functional assessment using Ussing Chamber analysis. Results: A Cftr ( Δ9/Δ9 ) mouse model presented with intestinal obstructions, and at time of weaning (21 days). Cftr ( Δ9/Δ9 ) mice had a survival rate of 83% that dropped to 38% by day 50. Histological sections of the small intestine from Cftr ( Δ9/Δ9 ) mice showed more goblet cells and mucus accumulation than samples from the Cftr ( Δ9/+ ) littermates. Airway epithelial cell cultures established from Cftr ( Δ9/Δ9 ) mice were not responsive to forskolin stimulation. Summary: The effect of Cftr exon 9 deletion on Cftr function was assessed and it was determined that the encoded Cftr isoform did not result in a milder “mouse CF disease phenotype,” suggesting that Cftr exon 9 is not dispensable, although further investigation in human CF pAECs would be required to confirm this observation. Frontiers Media S.A. 2022-03-22 /pmc/articles/PMC8981082/ /pubmed/35392567 http://dx.doi.org/10.3389/fphar.2022.868863 Text en Copyright © 2022 Martinovich, Kicic, Stick, Johnsen, Fletcher and Wilton. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Martinovich, Kelly M.
Kicic, Anthony
Stick, Stephen M.
Johnsen, Russell D.
Fletcher, Sue
Wilton, Steve D.
Investigating the Implications of CFTR Exon Skipping Using a Cftr Exon 9 Deleted Mouse Model
title Investigating the Implications of CFTR Exon Skipping Using a Cftr Exon 9 Deleted Mouse Model
title_full Investigating the Implications of CFTR Exon Skipping Using a Cftr Exon 9 Deleted Mouse Model
title_fullStr Investigating the Implications of CFTR Exon Skipping Using a Cftr Exon 9 Deleted Mouse Model
title_full_unstemmed Investigating the Implications of CFTR Exon Skipping Using a Cftr Exon 9 Deleted Mouse Model
title_short Investigating the Implications of CFTR Exon Skipping Using a Cftr Exon 9 Deleted Mouse Model
title_sort investigating the implications of cftr exon skipping using a cftr exon 9 deleted mouse model
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981082/
https://www.ncbi.nlm.nih.gov/pubmed/35392567
http://dx.doi.org/10.3389/fphar.2022.868863
work_keys_str_mv AT martinovichkellym investigatingtheimplicationsofcftrexonskippingusingacftrexon9deletedmousemodel
AT kicicanthony investigatingtheimplicationsofcftrexonskippingusingacftrexon9deletedmousemodel
AT stickstephenm investigatingtheimplicationsofcftrexonskippingusingacftrexon9deletedmousemodel
AT johnsenrusselld investigatingtheimplicationsofcftrexonskippingusingacftrexon9deletedmousemodel
AT fletchersue investigatingtheimplicationsofcftrexonskippingusingacftrexon9deletedmousemodel
AT wiltonsteved investigatingtheimplicationsofcftrexonskippingusingacftrexon9deletedmousemodel